Fond Farewells
May 13, 2020 3:10 pm Leave your thoughtsUCF bids farewell to two long-time and well-loved executives, who are leaving UCF to pursue professional opportunities elsewhere.
UCF bids farewell to two long-time and well-loved executives, who are leaving UCF to pursue professional opportunities elsewhere.
Today, 23.9% of voting shareholders of AbbVie, a U.S. pharmaceutical company, supported a United Church Funds-led shareholder resolution to report on the “feasibility of incorporating public concern over high drug price into the senior executive compensation arrangement.”
United Church Funds is proud to have coordinated a shareholder resolution with Gilead Sciences, Inc. that received 43.4% support at Gilead’s annual general meeting on May 6, 2020. The resolution requested the company to separate the position of the Chair of the Board from the CEO position.
United Church Funds talked with Rev. John H. Pomeroy, Co-Pastor at First Congregational Church of Pasadena, to learn about the church’s history, mission, and how they deepen their impact in the community through socially responsible investing.
Account Statements for April 2020 is available via the Client access link at the top of this page using your login and password. Please contact us if you do not have a login and password.
Matt Wagner, Director, Institutional Relationships, discussed with David Klassen, Chief Investment Strategist, the impact of COVID-19 on the global market, what recovery looks like and the benefits of diversification.
This article summarizes the markets and our funds’ performance for the month of March 2020, provided by our Chief Investment Strategist David A. Klassen.
The CARES Act contains provisions that will affect, among other things, charitable giving. UCF has prepared a list of resources and major takeaways on what the CARES Act means for charitable giving.
United Church Funds, along with investor members of the Interfaith Center on Corporate Responsibility, sent letters to the CEOs of 14 pharmaceutical companies, calling for a collaborative approach in the development of health technologies, including diagnostics, treatments and a vaccine in the global fight against COVID-19.
Account statements as of March 31, 2020 are available via the Client access link at the top of this page using your login and password. We have provided our investor letter from Charles Buck, President and CEO, and the preliminary performance information for Q1-2020.